Avadel PharmaceuticalsAVDL
13F holders, Q1 2024 (March 31)7holders
$16.89avg. 13F price*
At the end of Q1 2024, 7 institutions reported holding Avadel Pharmaceuticals Ltd. (AVDL) in their 13F filings. The largest holders were Cutter Capital Management, LP ($9.2M), Driehaus Capital Management LLC ($8.0M) and Marshall Wace, LLP ($6.5M).
- Company
- Avadel Pharmaceuticals Ltd.
- CUSIP
- G29687103
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $27.4M |
| Exits | 0 | $0 |
Ownership 7 holders
| Cutter Capital Management, LP | 3.53% | New | 541,926 | $9.2M |
| Driehaus Capital Management LLC | 0.08% | New | 475,437 | $8.0M |
| Marshall Wace, LLP | 0.01% | New | 383,641 | $6.5M |
| Stempoint Capital LP | 1.01% | New | 223,660 | $3.8M |
| Lindbrook Capital, LLC | 0.00% | New | 98 | $2K |
| Avior Wealth Management, LLC | 0.00% | New | 42 | $709 |
| Parallel Advisors, LLC | 0.00% | New | 42 | $709 |
"% of holder's portfolio" is AVDL's weight in each manager's 13F, not the share of Avadel Pharmaceuticals Ltd. the manager owns.